cyrilzakka/clinical-trials huggingface dataset:
Hyperthyroid Follow-Up Study

Background:

Hyperthyroidism is a common disease. It is very common for women. It is usually treated with Radioiodine (I-131). Some people think that this might cause cancer, even many years later. Past studies of people with hyperthyroidism have not been clear about cancer risks after I-131. Researchers want to look at a group of people with the disease who got I-131 many years ago. They want to look at how their health was months and years later.

Objective:

To learn more about disease risks in relation to radiation from I-131 treatment for hyperthyroidism.

Eligibility:

People who were part of the previous study. These are people who were diagnosed with hyperthyroidism at U.S. and U.K. hospitals from 1946 to 1964. About 95% of the participants have already died.

Design:

Researchers will examine data already collected by the past study. This includes data on participants later cancers and other health outcomes after they had I-131 treatment.

Researchers will compare that data to a National Death Index search.

This was already done for data up through 2003. This study will cover 2004 2014.

Researchers will not be in touch with study participants or their next of kin....

Hyperthyroidism (thyrotoxicosis) is a relatively common disease, especially among women, and radioiodine (I-131) administration is the treatment of choice for most adult patients. There is concern about possible carcinogenic effects of I-131 therapy, but previous studies of hyperthyroid patients have not presented clear results regarding cancer risks following I-131 treatment. There also is public concern regarding late health consequences of I-131 exposure as this radioiodine is one of the primary release products from nuclear power generation and a principal component in fallout from nuclear power plant accidents. The Thyrotoxicosis Therapy Follow-up Study (TTFUS) cohort, assembled in 1961, comprises 35,000 subjects treated for hyperthyroidism at over 20 medical centers in the US and one in Great Britain between 1946 and 1964. This is among the largest group of hyperthyroid patients that has been followed up for subsequent cancer and other health outcomes. The proposed mortality follow-up study will enable us to assess nearly lifetime risk of cancer and other diseases in this unique cohort. Mortality follow-up data will extend the observation through 2015, adding 15 more years, via linkage with the National Death Index search. Recently estimated I-131 radiation doses to various body organs will allow refined dose response analysis, providing most definitive assessment of the nature and magnitude of the risk of cancer and other disease associated with I-131 exposure as well as end-results of I-131 and other treatment for hyperthyroidism.

Eligibility Criteria:
* INCLUSION:

Individuals treated for hyperthyroidism registered within the Thyrotoxicosis Therapy Follow-up Study (TTFUS) cohort that was assembled in 1961.

EXCLUSION:

Any individual that was NOT treated for hyperthyroidism registered within the Thyrotoxicosis Therapy Follow-up Study (TTFUS) cohort that was assembled in 1961.
Causes of Visual Impairment Among Patients Applying for the Visually Disability Certification

Causes of Visual Impairment Among Patients Applying for the Visually Disability Certification in Upper Egypt: A Retrospective Study

There are at least 2.2 billion individuals with near- or far-sightedness worldwide. Nearly half of these cases-at At least 1 billion-have untreated vision impairment that may have been avoided. The leading cause of blindness or impaired distant vision among these 1 billion people is diabetic retinopathy (3.9 million), age-related macular degeneration (8 million), cataracts (94 million), refractive error (88.4 million), and glaucoma (7.7 million). Presbyopia (826 million) is the primary ailment that impairs close vision.

According to estimates, there are four times as many cases of distant vision impairment in low- and middle-income areas as there are in high-income areas.

Aging populations and population expansion are predicted to raise the likelihood that more people may have visual impairment. Early on, irreversible severe visual impairment in young children can lead to delayed motor, verbal, emotional, social, and cognitive development, which can have long-term effects. Children of school age who are visually impaired may also perform less academically. The quality of life is significantly impacted by vision impairment in adult populations. Adults who are visually impaired may have greater rates of anxiety and depression as well as decreased employment rates.

Vision impairment in older persons can increase their risk of falling and breaking bones, walking difficulties, social isolation, and early admission into nursing homes or other care facilities.

According to estimates, vision impairment costs the world's economy $411 billion annually in lost productivity (purchasing power parity) . This amount is greatly above the predicted $25 billion cost gap incurred from treating vision impairment.

This study is to demonstrate the causes of visual impairment in upper Egypt among the different age groups and evaluate the possibility of preventing these disorders

Eligibility Criteria:
Inclusion Criteria:

* All patients referred to The Ministry of Social Solidarity with visual Disability in upper Egypt who were examined in the visual disability screening program from 2020-2024.

Exclusion Criteria:

* The patients who had decreased vision but did not fit with the WHO definition of visual disability.
Anastrozole and Fulvestrant Compared to Anastrozole as Adjuvant Treatment of Postmenopausal Patients With Breast Cancer

Purpose is to compare the frequency of events (presence of Disseminated Tumour Cells, clinical recurrence and/or death) after 1 and 2 years of adjuvant treatment with anastrozole and fulvestrant or anastrozole alone in patients with early breast cancer.


Eligibility Criteria:
Inclusion Criteria:

* Postmenopausal women with hormone receptor-positive early breast cancer and a positive Disseminated Tumour Cell immunocytochemical result from bone marrow aspiration prior to randomisation

Exclusion Criteria:

* Inflammatory and/or metastatic breast cancer.
* Current or previous malignancy within previous 5 years (other than Breast cancer or adequately treated non-melanoma skin cancer or in-situ cervical cancer).
* History of bleeding diathesis.
Iron Absorption From GDS Capsules II

Slow release iron capsules containing ferrous sulfate have been designed based on the gastric delivery system. Iron absorption from those capsules administered with and without meals will be measured using stable iron isotopes.


Eligibility Criteria:
Inclusion Criteria:

* female,
* age 18-50 years,
* max. body weight 65 kg,
* serum ferritin \< 30 µg/l

Exclusion Criteria:

* pregnancy,
* lactation,
* regular intake of medication,
* blood donation or significant blood losses over the past 4 months
rhTPO Mobilized Auto Cryo Platelets For GYN Patients Receiving Carboplatin

A Pilot Study of Transfusion of rhTPO-Derived Autologous Platelets Cryopreserved with ThromboSol and 2% DMSO in Patients with Gynecologic Malignancy Receiving Carboplatin


Eligibility Criteria:
INCLUSION CRITERIA:

* Patients with gynecologic malignancy for whom treatment with carboplatin is indicated.
* Age \>/= 15 years.
* Adequate hematologic, renal, and hepatic functions.
* Life expectancy \>/- 3 months. Karnofsky Performance Status \>/= 80.
* Signed informed consent form.

EXCLUSION CRITERIA:

* Patients with rapidly progressive disease.
* Pregnant or lactating women.
* Patients with comorbid condition which renders patients at high risk of treatment complication.
* History of CNS metastasis.
* Patients with significant cardiac disease (NYHA Class III or IV), dysrhythmia, or recent history of MI or ischemia, transient ischemic attack or CVA within the 6 months of study entry.
* Prior chemotherapy, immunotherapy, any experimental drug within 4 weeks, use of myeloid (G-CSF or GM-CSF) growth factors within 2 weeks or erythropoietin within 4 weeks.
* Use of any nitrosourea (BCNU, CCNU) or mitomycin - C within 6 weeks.
* Prior surgery or RT within 2 wks of study entry.
* Patients with history of prior high dose chemotherapy with stem cell transplant or with history of prolonged thrombocytopenia (\> 2 weeks).
* History of leukemia.
* History of any platelet disorders including ITP, TTP or bleeding disorders.
* History of \> 3 prior chemotherapy regimens (all platinum regimens will be counted as 1 regimen).
* Demonstrated lack of response to platinum-based therapy.
Trial of Active Immunotherapy With Globo H-KLH (OPT-822/821) in Women Who Have Non-Progressive Ovarian Cancer

The purpose of this study is to evaluate the effect of OPT-822/OPT-821 on improving Progression-Free Survival (PFS) in subjects who have non-progressive epithelial ovarian, fallopian tube, or primary peritoneal cancer after cytoreductive surgery and platinum-based chemotherapy as initial treatment for primary disease or as salvage treatment for first relapse.


Eligibility Criteria:
Inclusion Criteria:

* Female subjects ≥ 21 years of age with histologically confirmed ≥ stage II epithelial ovarian, fallopian tube, and primary peritoneal cancer at diagnosis
* Who have not progressed after initial treatment with cytoreductive surgery and at least 4 cycles of platinum-based chemotherapy.

OR

* Female subjects ≥ 21 years of age with first relapsed epithelial ovarian, fallopian tube, and primary peritoneal cancer (regardless of stage at diagnosis)
* Who have not progressed after received at least 4 additional cycles of platinum-based chemotherapy with or without having undergone secondary cytoreductive surgery .

Exclusion Criteria:

* Subjects with evidence of disease progression according to the GCIG CA125 criteria or RECIST 1.1 criteria.
* Subjects who are currently receiving any other concomitant anticancer therapy.
* Subjects with evidence of extra-abdominal metastasis.
Registry Study for Patients With Chronic HBV Receiving Nucleotide Therapy

This registry will remain open for approximately 5 years (4 years of enrollment + 1 year of follow up). Subjects will be followed until Orthotopic Liver Transplant (OLT), resolution of liver decompensation, death, or conclusion of the registry.


Eligibility Criteria:
Key Inclusion Criteria:

* Estimated glomerular filtration rate (Cockcroft-Gault method)using actual body weight of ≥ 50 mL/min at time of entry into registry
* Negative serologies for HIV, hepatitis C virus (HCV), and/or hepatitis D virus (HDV)
* No history of solid organ or bone marrow transplant
* Currently receiving or anticipated to receive anti-HBV nucleoside/nucleotide therapy within 6 months of inclusion into registry

Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Prevention of Ileus After Gynecologic Surgery Using Chewing Gum

This study will attempt to determine if the use of chewing gum can cause the early return of bowel function after gynecologic surgery.


Eligibility Criteria:
Inclusion Criteria:

* All female patients 18 years of age or older undergoing surgery for any gynecologic procedure which the peritoneum is entered and general anesthesia is administered.
* Disease State will not affect inclusion in the study. Women with previous surgeries or other medical conditions will be included as will those undergoing an initial operation.

Exclusion Criteria:

* Patient deemed legally incompetent to sign their own consent
* Women under the age of 18
* Patients lacking their own or a false set of teeth
Comparing Efficacy Between Anti-microtubule and Non-anti-microtubule as 3th Therapy After 2nd Line EGFR-TKI Therapy

This is an observational prospective study that investigates only daily practice. The prescription of anti-cancer medicine is separated from the decision to include the patient in this study. In addition, the assignment of the patient to a particular therapy or therapeutic strategy is not decided in advance by this study protocol, but falls within current practice.

The patient who fulfils eligible criteria will be enrolled when starts to receive the second-line EGFR-TKI therapy. The frequency of tumor response evaluation by RECIST criteria follows the investigator's discretion as daily practice.


Eligibility Criteria:
Inclusion Criteria:

* At least one measurable lesion according to RECIST criteria
* Histologically or cytologically confirmed NSCLC of adeno histology
* Locally progressed or metastasized on or after first-line chemotherapy. The imaging evidence of disease progression can be either chest X ray, CT or MRI assessment on measurable lesions. If no measurable lesion is available, evaluable lesions are acce

Exclusion Criteria:

-
Evaluating Unilateral Deep Brain Stimulation in Patients With Obsessive Compulsive Disorder

The investigators previously showed that deep brain stimulation (DBS) in the bed nucleus of the stria terminalis (BNST) reduces symptoms in patients with severe obsessive-compulsive disorder (OCD). Although most patients now receive bilateral stimulation, multiple studies suggest that stimulation of the left BNST might be equally effective.

In this study, the investigators will evaluate the effect of unilateral stimulation in OCD patients who currently receive bilateral BNST stimulation to treat their symptoms. We hypothesize that unilateral stimulation of the left BNST will reduce anxious and depressive symptoms, compared to no stimulation.

The study entails a double-blinded, randomized cross-over design during which every patient undergoes four stimulation conditions: stimulation of the left, right or bilateral BNST, or no stimulation. During every condition, which takes about fifteen minutes, the patient is exposed to an individually determined stimulus that normally elicits OCD-related symptoms. The patients are then asked to fill out a short questionnaire to evaluate the severity of their symptoms during the four conditions. At the end of the cross-over phase, the stimulation parameters of each patient are restored.


Eligibility Criteria:
Inclusion criteria:

* Clinical diagnosis of obsessive-compulsive disorder
* Implanted with DBS system in the bilateral BST (or max. 4mm removed from the BST outline)
* At least three months of chronic BST stimulation
* Compulsive behavior can be provoked within a clinical setting

Exclusion criteria:

* Personality changes evoked by chronic DBS
* Cognitive impairment
AL-15469A for the Treatment of Bacterial Conjunctivitis

The purpose of the study is to determine whether AL-15469A is safe and effective in the treatment of bacterial conjunctivitis.


Eligibility Criteria:
Inclusion Criteria:

* Signs \& Symptoms of conjunctivitis

Exclusion Criteria:

* Under 1 mo. age
Smoking Cessation With Smokeless Tobacco, Nicotine Tablets and Nicotine Patches

To test if smokeless tobacco is more effective than nicotine buccal tablets in smoking cessation compared with a control group with low dose nicotine patches.

Also retreatment will be tested with smokeless tobacco every 6 months in failures for 1½ year. Adherence to the program will be enhanced by assessment of cholesterol, blood pressure, lung function and body weight every 6 months for 2 years.

This is an open randomized controlled trial with 3 groups testing smokeless tobacco in smoking cessation: 200 smokers will get smokeless tobacco for 3 months, 200 will get nicotine buccal tablets for 3 months and 200 will get 7-mg nicotine patches for 3 months (control arm). After ½, 1 and 1½ a year failures will get smokeless tobacco in the first 2 groups, while only 7 mg nicotine patches in control group until 1½ year where failures in this group also will get smokeless tobacco. Every ½ year cholesterol, blood pressure, lung function and BMI will be assessed and used to enhance adherence of the participants in this trial.

Eligibility Criteria:
Inclusion Criteria:

* smokers (\>7 cig/day)
* Healthy
* Allowed: treated hypertension, diabetes treated with tablets, increased cholesterol,other "mild" diseases
* mild asthma and COPD,
* Motivated to quit smoking
* Motivated to follow the protocol
* Motivated to use medication in this trial

Exclusion Criteria:

* Severe diseases
* Psychiatric diseases
* Used NRT or Zyban the last 2 weeks
* Stopped smoking \>2 days during last 3 months
* More than 6 alcoholic drinks per day
* Smokes other products than cigarettes
* Pregnant of lactating
MiDAS II (Mild® Decompression Alternative to Open Surgery): Vertos Mild Patient Evaluation Study

This is a multi-center, prospective, patient outcomes assessment of Minimally Invasive Lumbar Decompression with the Mild® devices in patients with symptomatic central canal spinal stenosis.


Eligibility Criteria:
Inclusion Criteria:

* Symptomatic lumbar spinal stenosis (LSS) primarily caused by dorsal element hypertrophy.
* Prior failure of conservative therapy and Oswestry Disability Index (ODI) score \> 20%.
* Radiologic evidence of lumbar spinal stenosis (LSS), ligamentum flavum hypertrophy (typically \> 2.5 mm), confirmed by pre-op MRI and/or CT.
* Central canal cross sectional area clearly reduced per MRI/CT report.
* If present, anterior listhesis preferred ≤ 5.0mm and deemed stable by Investigator.
* Able to walk at least 10 feet unaided before being limited by pain.
* Available to complete 26 weeks of follow-up.
* A signed Informed Consent Form is obtained from the patient.
* Adults at least 18 years of age.

Exclusion Criteria:

* Prior surgery at intended treatment level.
* Compound fracture with interspinal retropulsion contributing to spinal stenosis.
* Disabling back or leg pain from causes other than LSS (e.g. acute compression fracture, metabolic neuropathy, or vascular claudication symptoms, etc.).
* Disc protrusion or osteophyte formation severe enough to confound study outcome.
* Facet hypertrophy severe enough to confound study outcome.
* Bleeding disorders and/or current use of anti-coagulants.
* Use of acetylsalicylic acid (ASA) and/or non-steroidal anti-inflammatory drug (NSAID) within 5 days of treatment.
* Epidural steroid administration within prior three weeks (of procedure).
* Inability of the patient to lie prone for any reason with anesthesia support (e.g.chronic obstructive pulmonary disease (COPD), obesity, etc.).
* Metabolic wound healing pathologies deemed by Investigator to compromise study outcomes.
* Dementia and/or inability to give informed consent.
* Pregnant and/or breastfeeding.
* On Workman's Compensation or considering litigation associated with back pain.
A Safety and Tolerability Study of ABT-089 in Adults With Attention Deficit-Hyperactivity Disorder (ADHD)

The objective of this study is to evaluate the long-term safety and tolerability of ABT-089 in adults with ADHD.


Eligibility Criteria:
Inclusion Criteria:

* The subject was randomized into Study M06-855 and completed treatment in Periods 1 and 2 and the 2-week Extension Period
* If female, subject must be either postmenopausal for at least 1 year, surgically sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy), or practicing at least a method of birth control throughout the study
* If female, the result of a pregnancy tests are negative
* The subject is judged to be in generally good health

Exclusion Criteria:

* More than 7 days have elapsed since the last dose of study drug in Study M06-855
* The subject has taken any ADHD medication between the last dose of study drug in Study M06-855 and the first dose of study drug in the current study
* The subject anticipates a move outside the geographic area
Assiut University Children Hospital Egypt

Frequency and outcomes of mechanical ventilation In intensive care unit at Assiut university children hospital.

Data will be extracted from the files of the patients which will include the following:

History Examination Investigations Cause of mechanical ventilation (status epilepticus,respiratory failure and other) First attempt success rate

Eligibility Criteria:
Inclusion Criteria:

* Patients who are mechanically ventilated
* age:One month to 18 years.
* sex:both male and female
* duration:for one year
* type of the study:retrospective
* site :intensive care unit at Assiut university children hospital

Exclusion Criteria:

* patients who are intubated outside Assiut university children hospital.
12 weekS Adjuvant dOcetaxel Plus trastuzumaB in Patients With Small, Node-negative, HER2-positive Breast cancER (SOBER)

This phase II trial aims to study the efficacy and safety of 12 weeks adjuvant docetaxel plus trastuzumab in patients with tumors ≤1cm, node-negative, HER2-positive breast cancer.

Many clinical trials has showed the superiority of combining trastuzumab to chemotherapy in the treatment of HER2 positive early breast cancer with tumor size ≥1cm or node metastasis.But in pT1n0m0 breast cancer patients, patients with HER2 positive tumor show worse prognosis than those with HER2 negative tumor.A short duration of trastuzumab administration contaminately with chemotherapy may have similar efficacy and lowerer toxiticy compared with standard one year therapy.Our study aims to study the efficacy and safety of 12 weeks adjuvant docetaxel plus trastuzumab in patients with tumors ≤1cm, node-negative, HER2-positive breast cancer.

Eligibility Criteria:
Inclusion Criteria:

Women aged ≥18 years

Have finished radical operation

Pathologically confirmed dignosis of infiltrating primary breast cancer

According to AJCC ,pT≤1cm, pN0,no evidence for metastasis

Operation specimens are available for ER, progesterone receptor (PR) and Her2 detection, patients should be Her2 positive tumor (3+ by IHC or FISH+ )

Has Eastern Cooperative Oncology Group (ECOG) Performance Score 0-1,expected survival time \> 12 months

Adequate bone marrow function,adequate liver and renal function,and adequate coagulation function.

Women with potential child-bearing must have a negative pregnancy test (urine or serum) within 7 days of drug administration and agree to use an acceptable and effective method of contraception to avoid pregnancy during the study.

Written informed consent according to the local ethics committee requirements.

Exclusion Criteria:

pT\>1cm or node positive

Metastatic breast cancer

Any prior systemic or loco-regional treatment of breast cancer, including chemotherapy in 28 days

With a history of malignant tumor except uterine cervix cancer in situ or skin basal cell carcinoma

Patients with medical conditions that indicate intolerant to adjuvant chemotherapy and related treatment, including severe infection, coagulation disorder,active peptic ulcer, coagulation disorder, connective tissue disease or myelo-suppressive disease

Has symptomatic peripheral neuropathy \> grade 2 according to NCI

Known severe allergy to any drugs in this study

Has cadiac Dysfunction or lung dysfunction defined as follows:

1. grade ≥3 CHF according to NCI CTCAE v 4.0 or NYHA≥II
2. angina which requires drug control ,cardiac infraction,and any other vascular disease with apparent clinical symptoms
3. uncontrolled high-risk arryhthmia
4. unconrolled hypertension

Has active hepatitis B or hepatitis C with abnormal liver function tests (LFTs) or is known to be HIV positive

Patient is pregnant or breast feeding

-